

CONFERENCE

THE ANTIBODY SERIES 2021

BRINGING TOGETHER EXPERTS TO
DISCUSS INNOVATION IN ANTIBODY
DISCOVERY AND DEVELOPMENT

September 8th | 9:00am - 10:00pm
FairJourney Biologics - Rua de Delfim Ferreira 760 | 4100-199 Porto

From 9:00am - 5:00pm
Attendees arrival and check-in at the conference

From 9:00am - 6:00pm
Guided tours through the new building

6:00pm - 7:30pm
Welcome drink

7:30pm - 10:30pm
Standing dinner

8th & 9th
September 2021

FairJourney Biologics
Porto Palácio Hotel



THE ANTIBODY SERIES 2021

BRINGING TOGETHER EXPERTS TO DISCUSS INNOVATION IN ANTIBODY DISCOVERY AND DEVELOPMENT

9th September

8:00am to 6:30pm

Porto Palácio Hotel

8:00am - 8:30am

Last minute check-in at the conference

8:45am - 9:00am | **Keynote Presentation with Introduction by Session Chair**

Live



ALEXEY LUGOVSKOY – COO at DragonFly Therapeutics

PhD in Biophysics from Harvard University. Prior to joining Dragonfly, Alex served as CDO of Morphic Therapeutics, VP of Therapeutics of Merrimack Pharmaceuticals, and as an Associate Director of Drug Discovery at Biogen. Alex is co-author of over one hundred patents and manuscripts.

9:00am - 10:00am | **Pharmaceuticals: From chemicals to biologicals and back again?**

Virtual/Live



SIR GREGORY WINTER – Nobel Prize Laureate

PhD at the MRC Laboratory of Molecular Biology; pioneer of humanised and fully human antibody therapeutics, and of antibody libraries on phage. He was co-founder and a Director of Cambridge Antibody Technology, and is now co-founder and a Director of Bicycle Therapeutics.

10:00am - 10:30am

Coffee Break

10:30am - 11:30am | **Organoids to model human disease**

Live



HANS CLEVERS – Group leader/Professor at Hubrecht Institute

MD, PhD degree from the University Utrecht, the Netherlands. Hans Clevers was Professor in Immunology at the University Utrecht and, since 2002, Professor in Molecular Genetics. Hans was also Director of the Hubrecht Institute in Utrecht and he was President of the Royal Netherlands Academy of Arts and Sciences (KNAW). Recently he was director Research of the Princess Máxima Center for paediatric oncology.

11:30am - 12:30pm | **The Therapeutic Antibody (R)evolution**

Live



TON LOGTENBERG – Founder of Merus N.V.

PhD in Molecular Immunology from the University of Utrecht. Ton served as the CSO from 2000-2003 and a founder of Merus N.V., where he served as the CEO since 2003 and post IPO, from 2016-2020 as the President, CEO and Principal Financial Officer. With more than 25 years of experience in antibody engineering.

12:30pm - 1:30pm

Lunch Break

1:30pm - 2:30pm | **Antibody tailoring for success**

Live



MARIA PAJUELO – Co-founder and CSO at FJB

PhD in Biotechnology from the Catholic University in Porto. Maria initiated her career in 2006 at Ablynx, where she worked on the discovery and engineering of Nanobodies® as Scientist-Team leader until 2012. Maria is co-inventor in various patent applications on antibodies and technologies and co-author on 13 Peer Reviewed Publications.



DANIELA TEIXEIRA – COO at FJB

PhD in Biomedical Sciences from the University of Arizona and University of Porto. Daniela started her career in 2008 as an Associate Scientist at Ablynx where she worked on the identification of Nanobodies®. With more than 5 co-authored publications, Daniela joined FairJourney Biologics in 2012.



TERESA BARATA – Head of PSD and Flow Eighteen38

PhD in Chemistry from the UCL School of Pharmacy. Prior to Flow Eighteen38, Teresa was in the UK for over 10 years. She worked with biotherapeutics, in the fields of characterization, formulation development and product design and optimization. Co-author in 16 publications and co-inventor of one patent.



JOHN MCCAFFERTY – Founder and CSO at IONTAS

PhD, John was co-founder of CAT and inventor of antibody-phage display. In 2012, John founded IONTAS, creating the next generation antibody discovery technology - Mammalian Display - allowing discovery of IgG formatted antibodies directly from very large mammalian display libraries. John is author of more than 125 publications.

THE ANTIBODY SERIES 2021

BRINGING TOGETHER EXPERTS TO DISCUSS INNOVATION IN ANTIBODY
DISCOVERY AND DEVELOPMENT

9th September

8:00am to 6:30pm

Porto Palácio Hotel

2:30pm - 3:15pm | Antibody treatments towards Neurological disease

Live



ALLAN JENSEN – VP at Lundbeck

PhD in Molecular Biology at Aarhus University. Allan is an expert in discovery and preclinical development of antibody-based drugs and has several years of experience from various positions in the biotech and pharmaceutical industry. Before joining HiFiBio in 2014, he was Director of Science and Technology at Pfizer, Global Biotherapeutic Technologies.

3:15pm - 4:00pm | Developing and optimization of T-cell retargeting therapies

Live



LIODMILA TCHISTIAKOVA – EIR at Third Rock Ventures

PhD in Biochemistry from Shemyakin Institute of Biorganic Chemistry, Russian Academy of Sciences. Prior to Third Rock Ventures, Lioudmila spent 25+ years in pharmaceutical industry including Wyeth and Pfizer where she was leading development of therapeutic antibodies on many programs from idea to IND. Lioudmila has also co-authored more than 50 scientific publications, book chapters and patents.

4:30pm - 5:15pm | Antibodies changing human macrophage functionality via engaging novel targets to treat cancer

Live



TATIANA NOVOBRANTSEVA – CSO and co-founder of Verseau

PhD in Immunology from the University of Cologne. Tatiana has served as Head of Research and Development since Verseau's inception. Prior, Tatiana worked at multiple companies focusing on immunological aspects of drug development across different stages and therapeutic modalities in a variety of autoimmune, cancer and rare disease indications.

5:15pm - 6:15pm | Closing Presentation

Virtual/Live



TIM VAN HAUWERMEIREN – Co-founder and CEO at argenx SE

eMBA and General Management from Vlerick Leuven-Gent Management School. Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors, including Ablynx and Procter & Gamble.



HANS DE HAARD – Co-founder and CSO at argenx SE

PhD in Molecular Immunology from the University of Maastricht. Hans is a serial pioneer of antibody platforms and has been active in the antibody engineering field since 1989. From the discovery of llama VHH-based products to setting up the Nanobody®, Hans has discovered numerous therapeutic antibody leads with some already in the clinic.

6:15pm - 6:30pm

Closing Keynote by Session Chair

6:30pm - 8:00pm

Cocktail at the Lounge Rooftop of FairJourney Biologics

8:00pm

Formal Dinner at FairJourney Biologics New Building